Insmed Incorporated, which is developing Arikace liposomal amikacin for inhalation, has appointed Donald J. Hayden, Jr. as Executive Chairman of its Board of Directors, effective immediately. He has been serving as Chairman of the board of directors since the end of 2010 when Insmed merged with Transave, and he will continue to focus on the development of Arikace along with strategic planning and corporate development.
Insmed President and CEO Timothy Whitten said, “We are pleased that Don has agreed to serve as Executive Chairman of the Company. I have worked very closely with Don over the past several years, and he has been intimately involved in developing the Company’s plan for Arikace. Don has a long record of success in the pharmaceutical and biotechnology industries, and his insights and extensive executive-level experience will continue to be tremendous assets as we move forward with our growth and development initiatives.”
“It is a privilege to have been asked by my fellow Board members to serve as Executive Chairman of Insmed at this important stage of the Company’s development. I look forward to working with Tim and the management team as we continue to advance Arikace and work to build value for shareholders,” Hayden responded.
Read the Insmed press release.
